Compare IGIC & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IGIC | CMPX |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | Jordan | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 926.7M |
| IPO Year | N/A | N/A |
| Metric | IGIC | CMPX |
|---|---|---|
| Price | $23.82 | $5.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $30.33 | $13.44 |
| AVG Volume (30 Days) | 58.8K | ★ 2.5M |
| Earning Date | 02-24-2026 | 02-26-2026 |
| Dividend Yield | ★ 4.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.81 | N/A |
| Revenue | ★ $525,808,999.00 | N/A |
| Revenue This Year | $17.79 | N/A |
| Revenue Next Year | $3.05 | N/A |
| P/E Ratio | $8.45 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.82 | $1.33 |
| 52 Week High | $27.76 | $6.25 |
| Indicator | IGIC | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 41.81 | 58.06 |
| Support Level | $23.36 | $5.09 |
| Resistance Level | $24.37 | $6.25 |
| Average True Range (ATR) | 0.63 | 0.43 |
| MACD | -0.17 | 0.05 |
| Stochastic Oscillator | 25.54 | 64.04 |
International General Insurance Holdings Ltd is an international specialist commercial insurer and a reinsurer, underwriting a diverse portfolio of specialty lines. The company operates in a portfolio of Energy, Property, Construction, Engineering, Ports and terminals, Financial Institutions, General Aviation, Professional Indemnity, Casualty, Directors and Officers, Political Violence, Forestry, and Treaty Reinsurance. Its operating segment includes Specialty Longtail; Specialty Short tail and Reinsurance.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.